{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Evans JP"],"funding":["National Center for Advancing Translational Sciences","NICHD NIH HHS","NCATS NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","NCI NIH HHS","National Institutes of Health"],"pagination":["1093-1102.e3"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035359"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(8)"],"pubmed_abstract":["Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicr"],"journal":["Cell host & microbe"],"pubmed_title":["Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2."],"pmcid":["PMC9035359"],"funding_grant_id":["R01 HD095881","UL1 TR002733","U54 CA260582","R01 HL096376","R01 AI150473","KL2 TR002734"],"pubmed_authors":["Xu K","Faraone J","Evans JP","Mallampalli R","Gumina RJ","Zhou T","Mohler PJ","Zheng YM","Liu SL","Zeng C","Qu P","Saif LJ","Lozanski G","Carlin C","Oltz EM","Bednash JS"],"additional_accession":[]},"is_claimable":false,"name":"Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.","description":"Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-31T21:00:19.235Z","creation":"2025-02-19T04:21:16.569Z"},"accession":"S-EPMC9035359","cross_references":{"pubmed":["35526534"],"doi":["10.1016/j.chom.2022.04.014"]}}